NICE says lenvatinib should be available on NHS
NICE recommends lenvatinib, also known as kisplyx, be given in conjunction with another drug called everolimus. This drug-duo is recommended as an option for people who have previously
Amberstone Biosciences has signed a partnership and licence agreement with Shanghai Henlius Biotech for conditionally activated T-cell engager candidates to treat solid tumours.
Ramucirumab, which is an antiangiogenic therapy, was evaluated in combination with cisplatin and capecitabine or 5-FU (5-fluorouracil) for the treatment of HER2-negative metastatic gastric or gastroesophageal junction (GEJ)
The study demonstrated that the Tecentriq combination has more effectively reduced the disease progression in patients compared to those who received Avastin plus chemotherapy. IMpower150 is a multicenter,